T 0317/20 (NGF antagonist for treatment of osteoarthritis/RINAT) of 29.07.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T031720.20210729
- Date of decision
- 29 July 2021
- Case number
- T 0317/20
- Petition for review of
- -
- Application number
- 10184427.2
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Methods for treating osteoarthitis pain by administering a nerve growth factor antagonist and compositions containing the same
- Applicant name
- Rinat Neuroscience Corp.
- Opponent name
- Regeneron Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 105European Patent Convention Art 83European Patent Convention R 76(2)(c)European Patent Convention R 89(2)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Intervention of assumed infringer - notice of intervention
Intervention of the assumed infringer - admissibility of intervention during appeal proceedings
Intervention of the assumed infringer - admissible (yes)
Sufficiency of disclosure - (no)
Amendment after summons - exceptional circumstances (no)
Amendment after summons - cogent reasons (no)
Amendment after summons - taken into account (no) - Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.